CRISPR Therapeutics AG (CRSP) Receivables - Accured (2019 - 2023)

CRISPR Therapeutics AG (CRSP) has 5 years of Receivables - Accured data on file, last reported at $2.2 million in Q1 2023.

• For the quarter ending Q1 2023, Receivables - Accured changed 0.0% year-over-year to $2.2 million; the trailing twelve-month figure through Mar 2023 stood at $2.2 million (changed 0.0% YoY), and the FY2022 full-year result was $2.2 million, changed 0.0% from the prior year.
• Receivables - Accured held at $2.2 million in Q1 2023, from $2.2 million in the prior quarter.
• In the past five years, Receivables - Accured ranged from a high of $2.2 million in Q1 2021 to a low of $600000.0 in Q4 2019.
• A 5-year average of $1.8 million and a median of $2.2 million in 2021 frame the typical range for Receivables - Accured.
• Across the five-year window, Receivables - Accured changed 0.0% in 2020 and soared 268.67% in 2021, its largest moves.
• Tracing CRSP's Receivables - Accured over 5 years: stood at $600000.0 in 2019, then changed by 0.0% to $600000.0 in 2020, then soared by 268.67% to $2.2 million in 2021, then changed by 0.0% to $2.2 million in 2022, then changed by 0.0% to $2.2 million in 2023.
• Business Quant data shows CRSP's Receivables - Accured at $2.2 million in Q1 2023, $2.2 million in Q4 2022, and $2.2 million in Q3 2022.